Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
10 analysts have shared their evaluations of Corteva (NYSE:CTVA) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 3 | 5 | 2 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 0 | 0 | 0 |
3M Ago | 2 | 4 | 2 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $61.3, a high estimate of $66.00, and a low estimate of $53.00. This upward trend is apparent, with the current average reflecting a 4.89% increase from the previous average price target of $58.44.
A comprehensive examination of how financial experts perceive Corteva is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Aleksey Yefremov | Keybanc | Raises | Overweight | $66.00 | $63.00 |
Christopher Kapsch | Loop Capital | Raises | Buy | $65.00 | $57.00 |
Kristen Owen | Oppenheimer | Raises | Outperform | $62.00 | $60.00 |
Arun Viswanathan | RBC Capital | Raises | Outperform | $64.00 | $56.00 |
Aleksey Yefremov | Keybanc | Raises | Overweight | $63.00 | $62.00 |
Richard Garchitorena | Wells Fargo | Raises | Overweight | $65.00 | $54.00 |
Benjamin Theurer | Barclays | Raises | Equal-Weight | $55.00 | $50.00 |
Laurent Favre | Exane BNP Paribas | Announces | Neutral | $53.00 | - |
Chris Parkinson | Mizuho | Lowers | Buy | $56.00 | $59.00 |
Joshua Spector | UBS | Lowers | Buy | $64.00 | $65.00 |
Capture valuable insights into Corteva's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Corteva analyst ratings.
Corteva is an agriculture pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop chemicals products. Seeds generate a little over half of profits with the remainder coming from crop protection chemicals. Although Corteva operates globally, around half of revenue comes from North America.
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Corteva's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -3.08%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -6.82%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Corteva's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.01%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Corteva's ROA stands out, surpassing industry averages. With an impressive ROA of -0.59%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CTVA